Cardiovascular safety of the tyrosine kinase inhibitor nintedanib

Articles reviews evidence supporting the hypothesis that VEGF inhibition by nintedanib may partly account for its link to MI and discusses possible actions for a safe implementation of nintedanib in clinical practice, building on experience with TKIs acquired in cardio‐oncology.

British Journal of Clinical Pharmacology